Publication date: Aug 01, 2024
Our retrospective study aimed to determine how pulmonary arterial hypertension (PAH) influences the clinical outcomes of COVID-19 admissions by using data from the 2020 nationwide inpatient sample (NIS). Among the 1,018,915 adults who were hospitalized with COVID-19 in 2020, 155 also had a PAH diagnosis. After adjusting for all baseline demographics and co-morbidities through multivariate analysis, we found that in patients admitted with a principal diagnosis of COVID-19, PAH was not associated with an increased risk of mortality compared to those without PAH. (adjusted OR 0. 58 [95% CI 0. 2-1. 6] p=0. 3). In addition, patients with both COVID-19 and PAH showed no statistically significant difference in the odds of requiring mechanical ventilation (adjusted OR 1. 1 [95% CI 0. 5-2. 6] p=0. 9), vasopressor needs (adjusted OR 0. 4 [95% CI 0. 1-3. 5] p=0. 4), acute kidney injury necessitating renal replacement therapy(adjusted OR 0. 7 [95% CI 0. 3-1. 7] p=0. 5), mean length of stay (LOS) (11. 1 vs. 7. 5 days), adjusted difference 3. 1 [95% CI -3. 8- 10. 1] p=0. 37) or mean total hospitalization charges ($195,815 vs $79,082, adjusted difference 107,146 [95% CI -93,939 – 308,232] p=0. 29). Further studies are needed to investigate this subpopulation during the post-vaccination era to observe the effects of outcomes in these patients.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | pulmonary arterial hypertension |
| disease | VO | vaccination |
| drug | DRUGBANK | Aminohippuric acid |
| disease | MESH | COVID-19 |
| disease | MESH | morbidities |
| disease | MESH | acute kidney injury |
| disease | MESH | Pulmonary hypertension |
| disease | MESH | Viral infections |